Effects of imeglimin in patients with type 2 diabetes mellitus

Effects of imeglimin in patients with type 2 diabetes mellitus - Effects of imeglimin in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049071

Enrollment

Registered

2022-10-01

Start date

2022-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes attending the Department of Diabetes and Metabolism HbA1c between 7.0% and 10%. Patients with written consent

Exclusion criteria

Exclusion criteria: Patients with a history of severe ketoacidosis, diabetic coma, or pre-coma Patients with malignant tumors and other serious diseases with poor prognosis Impaired renal function: eGFR <45 mL/min/1.73 m2

Design outcomes

Primary

Measure	Time frame
Blood glucose and skeletal muscle related parameters	—

Countries

Japan

Contacts

Public Contactsatoshi ida

Ise Red Cross Hospital Department of diabetes and metabolism

bboy98762006@yahoo.co.jp0596282171

Outcome results